News

gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms

ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced…

12 months ago

PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

·   Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years ·   VoxNova will be responsible…

12 months ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

12 months ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company…

12 months ago

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity Continue to expect topline data from Phase 2 GI.1 challenge…

12 months ago

Alignment Health Welcomes New Chief People Officer as It Scales to Serve More Seniors Nationwide

Seasoned HR executive Melinda Kimbro will drive tech-enabled Medicare Advantage company’s people strategy, ensuring organizational excellence and boosting employee experience…

12 months ago

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More 

LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is very pleased to announce several exciting…

12 months ago

Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis

Key study results Key efficacy endpointsEblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile…

12 months ago

STRATA Skin Sciences Secures additional $12 Million Financing with MidCap Financial

HORSHAM, Pa., July 06, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

12 months ago

Sharps Technology Provides Update on Commercialization Activities and is Highlighted in Med Tech Outlook Feature Article

Company advances commercialization of Securegard smart safety syringe product linethrough qualification programs with a major medical device company Production of…

12 months ago